Tscan Therapeutics Inc
(TCRX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 2,816 | 21,049 | 13,535 | 10,141 | 1,085 |
| Gross Profit | 2,816 | 21,049 | 13,535 | 10,141 | 1,085 |
| Operating Expenses | 137,637 | 114,507 | 80,171 | 58,782 | 27,318 |
| Operating Income | -134,821 | -93,458 | -66,636 | -48,641 | -26,233 |
| Interest Expense | 3,653 | 3,759 | 1,176 | 0 | 0 |
| Other Income | 10,975 | 7,999 | 1,591 | 16 | 106 |
| Pre-tax Income | -127,499 | -89,218 | -66,221 | -48,625 | -26,127 |
| Net Income Continuous | -127,499 | -89,218 | -66,221 | -48,625 | -26,127 |
| Net Income | $-127,499 | $-89,218 | $-66,221 | $-48,625 | $-26,127 |
| EPS Basic Total Ops | -1.14 | -1.36 | -2.75 | -4.17 | -28.52 |
| EPS Basic Continuous Ops | -1.14 | -1.36 | -2.75 | -4.17 | -28.52 |
| EPS Diluted Total Ops | -1.14 | -1.36 | -2.75 | -4.17 | -28.52 |
| EPS Diluted Continuous Ops | -1.14 | -1.36 | -2.75 | -4.17 | -28.52 |
| EPS Diluted Before Non-Recurring Items | -1.13 | -1.36 | -2.75 | -4.17 | N/A |
| EBITDA(a) | $-130,713 | $-88,097 | $-61,499 | $-45,313 | $-25,003 |